Expression of matrix metalloproteinases and their inhibitors in different immunohistochemical-based molecular subtypes of breast cancer

Ga-Eon Kim¹, Ji Shin Lee¹*, Yoo-Duk Choi¹, Kyung-Hwa Lee³, Jae Hyuk Lee¹, Jong Hee Nam¹, Chan Choi¹, Sung Sun Kim¹, Min Ho Park², Jung Han Yoon² and Sun-Seog Kweon³

Abstract

Background: Metalloproteinases (MMPs) and their tissue inhibitors of metalloproteinases (TIMPs) are involved in several key pathways of tumor growth, invasion and metastasis, but little is known about their expression according to different molecular subtypes of breast cancer. The aims of this study were to assess the prevalence and clinical significance of MMP and TIMP expression in invasive breast cancer and to determine its association with immunohistochemical-based molecular classification.

Methods: Tissue microarray sections were immunostained for estrogen receptor-α (ER-α), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), cytokeratin (CK) 5/6, epidermal growth factor receptor (EGFR) and with specific antibodies against MMP-1, 2, 7, 9, 11, 13, and 14 and TIMP-1, 2, and 3. Based on the immunostaining data from five of the markers used (ER-α, PR, HER2, EGFR and CK5/6), three major subtypes (123 luminal A, 31 basal-like, and 17 HER2-overexpressing) were selected.

Results: Statistically significant differences in the expression of MMPs and TIMPs among the three subtypes were found in tumoral MMP7 (P = 0.005), tumoral MMP-9 (P = 0.000), tumoral MMP-13 (P = 0.016) and stromal MMP-13 (P = 0.016). The incidence of tumoral MMP-9 expression in the HER2-overexpressing subtype was significantly higher than in the luminal A subtype (P = 0.021). Tumoral MMP-9 and stromal MMP-13 expression were significantly higher in the HER2-overexpressing subtype than in the basal-like subtype (P = 0.000 and P = 0.016, respectively). Tumoral MMP-7 expression was significantly higher in the basal-like subtype compared to luminal A (P = 0.007) and HER2-overexpressing subtype (P = 0.004). Tumoral MMP-13 showed a higher expression in the basal-like subtype than in the HER2-overexpressing subtype (P = 0.010). In multivariate analysis, stage and stromal MMP-1 expression were significantly related to overall survival. Stage was of independent prognostic significance for disease-free survival.

Conclusion: We found some variations in MMP and TIMP expression among the immunohistochemical-based molecular subtypes of breast carcinomas, suggesting differences in their tumor pathophysiology. Additional studies are needed to determine the mechanisms underlying the differences of MMP and TIMP expression in the molecular subtypes for the development of specific therapeutic targets for breast cancer subtypes.

Keywords: Breast cancer, Molecular subtype, Immunohistochemistry, Matrix metalloproteinase, Tissue inhibitor of metalloproteinase
Background

Breast cancer is the second most common malignancy in Korean women representing 16% of all female cancers [1]. Breast carcinoma encompasses a group of very heterogeneous diseases including a number of distinct entities with specific pathological features and biological behavior [2,3].

Microarray profiling of breast carcinoma has identified five distinct subtypes of tumors (luminal A, luminal B, normal breast-like, human epidermal growth factor receptor 2 (HER2)-overexpressing, and basal-like) that are associated with different clinical outcomes [4-7]. Although this classification system is based on extensive genetic profiling assays, a simplified method of classification based on immunohistochemical surrogates is appealing and more clinically useful. Based on the immunostaining data from five markers [estrogen receptor-α (ER-α), progesterone receptor (PR), HER2, cytokeratin (CK) 5/6, and epidermal growth factor receptor (EGFR)], breast carcinoma can be categorized as luminal A (ER-α+ and/or PR+ and HER2-); luminal B (ER-α+ and/or PR+ and HER2+); HER2-overexpressing (ER-α- and PR- and HER2+); basal-like (ER-α-, PR-, HER2- and EGFR or CK 5/6+); and unclassified (ER-α-, PR-, HER2-, EGFR-, and CK 5/6-) [8,9]. Compared with the luminal subtype, basal-like and HER2-overexpressing breast cancers are associated with worse overall and disease-free survival rates [6,7]. Basal-like carcinoma has a triple-negative phenotype (ER-α-, PR-, and HER2-); as a result, the majority of these tumors cannot be managed effectively with existing targeted treatment (including Trastuzumab and hormonal treatments) [10]. Therefore, there is a need for the development of new therapies specifically for basal-like breast cancer.

Matrix metalloproteinases (MMPs) and their tissue inhibitors of metalloproteinases (TIMPs) act in concert to control extracellular matrix turnover [11,12]. MMP and TIMP expression is altered in both benign and malignant tumors, as well as in invasion and metastasis which require breakdown and removal of the extracellular matrix [13,14]. The central role of MMPs and TIMPs in tumor invasion and metastasis makes them an attractive target for drug development [15].

Previous studies have shown the expression and activity of MMPs to be linked to the advanced stage of breast cancer, increased invasion of tumor cells and building of metastatic formations [16-18]. Likewise, it has been reported that TIMPs may be overexpressed and/or related to clinical outcome of breast carcinoma [16]. However, the association between MMP and TIMP expression and the distinct molecular subtypes of breast carcinoma has not been well investigated [17,19].

We designed this study to analyze different expression levels of MMPs and TIMPs in breast carcinoma with respect to immunohistochemical-based molecular classification and to determine their relationship to other clinical-pathological factors. MMPs and TIMPs, which are known to be involved in breast carcinogenesis (MMP-1, 2, 7, 9, 11, 13, and 14 and TIMP-1, 2, and 3), were selected and assessed using the immunohistochemistry of three major subtypes of invasive breast carcinomas (luminal A, basal-like, and HER2-overexpressing); based on the immunohistochemical findings of ER-α, PR, HER2, EGFR, and CK5/6.

Methods

Case selection

Histologic files of Chonnam National University Hospital, Gwangju, Korea from the period between 1997 and 2002 were searched for invasive breast carcinoma. We selected 204 cases with a minimum of 10 years of follow-up. Tumor tissue was obtained from patients with unilateral breast carcinoma after surgical resection. We excluded patients with distant metastases at the time of initial diagnosis or with bilateral breast carcinoma at diagnosis. Furthermore, patients who had received neoadjuvant therapy, or who had a prior history of any kind of cancer, were excluded from this study. All samples were obtained with informed consent under protocols approved by the institutional review board of the Chonnam National University Hospital. Full clinical and pathological data were collected and known for all participants.

Tissue microarray construction

The arrays were constructed with a 1.5 mm punch on the Beecher arrayer. The array layout in the grid format was designed using Microsoft Excel. Hematoxylin and eosin-stained sections were reviewed and the area of interest was marked out on the slide. Using a marker pen, the corresponding region was circled on the archival ‘donor’ paraffin block. The samples were then arrayed on to a ‘recipient’ blank block. Each sample was arrayed in triplicate to minimize tissue loss and overcome tumor heterogeneity.

Immunohistochemistry and silver-enhanced in situ hybridization

Tissue microarray sections were immunostained for ER-α, PR, HER2, CK 5/6, and EGFR and specific antibodies against MMP-1, 2, 7, 9, 11, 13, and 14 and TIMP-1, 2, and 3. Automated immunohistochemical staining was performed using the Bond-max system (Leica Microsystems, Bannockburn, IL), which is a device able to process up to 30 slides at a time. Slides carrying tissue sections that were cut from paraffin-embedded tissue microarray blocks were labeled and dried for 1 hour at 60°C. These slides were then covered by Bond Universal Covertiles (Leica Microsystems) and placed into the Bond-max instrument. All subsequent steps were performed by the automated instrument according to the manufacturer’s instructions (Leica Microsystems), in the following order: (1) deparaffinization
of tissue on the slides using Bond Dewax Solution (Leica Microsystems) at 72°C for 30 minutes; (2) heat-induced epitope retrieval (antigen unmarking) with Bond Epitope Retrieval Solution 1 (Leica Microsystems) for 20 minutes at 100°C; (3) peroxo block placement on the slides for 5 minutes at ambient temperature; and (4) incubation with ER-α (1:35, clone 1D5, DakoCytomation, Glostrup, Denmark), PR (1:150, clone PgR 636, DakoCytomation), HER2 (1:250, DakoCytomation), CK5/6 (1:50, clone D5/6 B4, DakoCytomation), EGFR (1:200, clone H11, DakoCytomation), MMP-1 (1:50, Thermo Fisher Scientific, Fremont, CA), MMP-2 (1:25, clone A-Gel VC2, Thermo Fisher Scientific), MMP-7 (1:200, clone ID2, Thermo Fisher Scientific), MMP-9 (1:50, Thermo Fisher Scientific), MMP-11 (1:100, clone SL3.05, Thermo Fisher Scientific), MMP-13 (1:25, clone VIII A2, Thermo Fisher Scientific), MMP-14 (1:50, Thermo Fisher Scientific), TIMP-1 (1:25, clone 102D1, Thermo Fisher Scientific), TIMP-2 (1:200, clone 3A4, Thermo Fisher Scientific), and TIMP-3 (1:50, clone Z188, Santa Cruz Biotechnology, Santa Cruz, CA) primary antibodies for 15 minutes at ambient temperature; (5) incubation with Post Primary Regent (Leica Microsystems) for 8 minutes at ambient temperature, followed by washing with Bond Wash Solution (Leica Microsystems) for 6 minutes; (6) Bond Polymer (Leica Microsystems) placement on the slides for 8 minutes at ambient temperature, followed by washing with Bond Wash and distilled water for 4 minutes; (7) color development with DAB (3,3’-diaminobenzidine tetrahydrochloride) as chromogen for 10 minutes at ambient temperature; and (8) hematoxilyn counterstaining for 5 minutes at ambient temperature, followed by mounting of the slides. Paraffin sections of normal breast were used as positive controls for CK5/6, sections of breast carcinoma were used for ER-α, PR, HER2, MMPs, and TIMPs positive controls, and a squamous cell carcinoma of the skin was used for EGFR’s positive control. The primary antibody incubation step was omitted in the negative control.

Tissue microarrays were digitized (Aperio Technologies, Vista, CA) and semi-quantified estimation for immunoreactivity was performed in all cases. Tumor cells that showed nuclear staining for ER-α or PR were considered ER-α+ or PR+, whereas all ER-α- or PR- cases showed a complete absence of tumor cell staining. Of note, low positive ER or PR (1-10% of tumor cell nuclei staining) and positive ER or PR (>10% of tumor cell nuclei staining) were collapsed into a single ER or PR ‘positive’ category for the purposes of this analysis. Results of HER2 immunostaining were scored according to the ASCO/CAP guidelines. HER2 immunostaining was considered positive when strong (3+) membranous staining was observed in at least 30% of tumor cells, whereas cases with 0 to 1+ were regarded as negative. Cases with equivocal (2+) result for HER2 immunostaining were retested by silver-enhanced in situ hybridization (SISH). HER2 SISH testing and scoring were performed as described previously below [20]. Briefly, INFORM® HER2 DNA and Chromosome 17 probes (Ventana Medical System) were done on the microarray sections using the Benchmark® automatic immunostaining device in accordance with the Ventana’s protocol. HER2 signals were scored according to the 2008 ASCO/CAP guidelines. Any degree of cytoplasmic immunostaining for CK 5/6 and any degree of distinct membranous staining for EGFR were considered as positive expression. A case was classified as positive if there was positive staining in any of the three cores from that case and negative if there was no immunostaining.

MMP and TIMP immunoreactivity in the tumor tissue and in the surrounding stromal tissue was evaluated. We could differentiate tumor cells from stromal cells based on their distinctive morphologies. Tumor cells are larger than stromal cells. In addition, tumor cells show nucleoli and are arranged in tubes, irregular nests, or solid sheets. Stromal cells are fibroblasts or mononuclear inflammatory cells. A scoring system was used to describe both the intensity of staining (negative, weak, moderate, and strong) and the proportion of positive cells (0%, 1-25%, 26-50%, 51-75%, and 76-100%) in each case. To enable the analysis of the individual immunostaining results, integer values were assigned to the intensity score (0–3) and to the proportion of stained cells (0–4). The percentages of MMP and TIMP immunoreactive cells were evaluated from two separate protein stained fields per core under 400x magnification. These values were added together to provide a single integrated score for each MMP or TIMP, and the average data of three cores were used for further analysis. Tumors having a final staining score of >2 were considered positive [5].

**Immunohistochemical-based molecular classification**

Cancers were categorized as luminal A (ER-α and/or PR+ and HER2-); luminal B (ER-α and/or PR+ and HER2+); HER2-overexpressing (ER-α-, PR-, and HER2+); basal-like (ER-α-, PR-, HER2- and EGFR+ or CK5/6); and unclassified (ER-α-, PR-, HER2-, EGFR-, and CK 5/6-).

**Statistical analysis**

Tumor characteristics and expression of MMPs and TIMPs were compared across different breast cancer subtypes using the exact χ² test for categorical data and the nonparametric Kruskal-Wallis test for continuous data. Survival curves were estimated using the Kaplan-Meier method. The distribution of survival was compared using the log-rank test. Multivariate analysis was performed using the Cox’s proportional hazard model. In the multivariate analysis, we included only parameters that achieved statistical significance for relapse-free survival or overall survival in the log-rank test.
For all statistical analyses, the SPSS system for personal computer (version 18.0 for windows; SPSS INC., Chicago, IL) was used and $P < 0.05$ was regarded as statistically significant.

**Results**

**Clinicopathologic characteristics**
Out of the 204 patients with invasive breast carcinoma we surveyed, 123 (60.3%) were luminal A; 17 (8.3%), luminal B; 31 (15.2%), basal-like; 17 (8.3%), HER2-overexpressing; and 16 (7.8%), unclassified (Figure 1). For the present study, we selected the three most frequent types: luminal A, basal-like, and HER2-overexpressing subtypes. Table 1 shows the clinicopathologic characteristics of the study subjects across the three subtypes of breast cancer. Our results did not show significant differences between the three types with regard to age, tumor size, nodal status, and stage. However, significant differences among the three subtypes of breast carcinoma were found for histologic grade ($P = 0.000$). Both the basal-like and HER2-overexpressing subtypes were associated with a higher grade than the luminal A group ($P = 0.000$ and $P = 0.000$, respectively).

**Expression of MMPs and TIMPs**
Immunostaining data was available for all markers in the basal-like and HER2-overexpressing subtypes. In the luminal A subtype, immunostaining data was available for all markers in 123 cases except for TIMP1. TIMP1 was available for interpretation in 122 of the 123 cases. Figure 2 shows the examples of tissue microarrays with immunostaining for MMPs and TIMPs. Immunostaining for each protein was localized to neoplastic cells but also visible in stromal cells around the tumor. Tumor cells showed a greater expression of MMPs and TIMPs than stromal cells except for MMP-1.

Tumoral MMP-7 ($P = 0.005$), tumoral MMP-9 ($P = 0.000$), tumoral MMP-13 ($P = 0.016$) and stromal MMP-13 ($P = 0.016$) expression showed statistically significant differences among the three subtypes (Table 2). The incidence of tumoral MMP-9 expression in the HER2-overexpressing subtype was significantly higher than in the luminal A subtype ($P = 0.021$) and the basal-like subtype ($P = 0.000$). Stromal MMP-13 expression was significantly higher in the HER2-overexpressing subtype than in the basal-like subtype ($P = 0.016$).

Tumoral MMP-7 expression was significantly higher in the basal-like subtype compared to the luminal A subtype ($P = 0.007$) and the HER2-overexpressing subtype ($P = 0.004$). Tumoral MMP-13 expression showed a higher expression in the basal-like subtype than in the HER2-overexpressing subtype ($P = 0.010$).

**Correlation with patient survival**
Survival data of the three subtypes was available for all 171 patients (mean follow-up 117.3 months, median, 131 months; range, 1–190 months). Forty-seven patients experienced local recurrence or metastasis (11 with local recurrence and 36 with distant metastases), and 124 remained disease free. There were 50 deaths due to breast carcinoma.

In univariate long-rank analysis, tumor size ($P = 0.000$), status of nodal involvement ($P = 0.000$), tumor stage...
and stromal MMP-1 expression \((P = 0.047)\) were significantly associated with overall survival (Figure 3). Tumor size \((P = 0.000)\), status of nodal involvement \((P = 0.000)\), tumor stage \((P = 0.000)\), and tumoral TIMP-3 expression \((P = 0.026)\) were significantly associated with disease-free survival (Figure 4). All statistically significant variables from the univariate analyses were entered into multivariate Cox regression analysis (Table 3). Multivariate analysis subsequently showed that stage and stromal MMP-1 expression were significantly related to overall survival. Stage was of independent prognostic significance for disease-free survival.

**Discussion**

Microarray profiling of invasive breast carcinomas has identified several distinct molecular subtypes of tumors [4-7]. In accordance with this view, we propose that molecular subtypes are likely to contain distinct MMP/TIMP patterns. In this study, we analyzed the differences in the immunoreactivity of MMPs (MMP-1, 2, 7, 9, 11, 13, and 14) and TIMPs (TIMP-1, 2, and 3) in breast carcinoma representing three subtypes, luminal A, HER2-overexpressing, and basal-like, based on immunohistochemical findings. We demonstrated that tumoral MMP-7, tumoral MMP-9, tumoral MMP-13 and stromal MMP-13 expression were statistically significantly different among the three subtypes.

Gene expression profiling with breast carcinomas has identified five distinct subtypes of the disease: luminal A, luminal B, normal breast-like, HER2-overexpressing, and basal-like [4-7]. Although these molecular subtypes correlate with prognosis and response to therapy, the use of gene expression profiling has been limited by issues such as cost, complexity, and technical expertise. Subsequent studies have proposed novel immunohistochemistry panels to classify breast cancer into five distinct subtypes. These panels use five markers (ER-α, PR, HER2, CK 5/6, and EGFR) to categorize molecular subtypes as luminal A (ER-α + and/or PR+ and HER2-); luminal B (ER-α + and/or PR+ and HER2+); HER2-overexpressing (ER-α- and

---

**Table 1 Clinicopathologic characteristics of each subtype**

|                | Luminal A \(n = 123\) | Basal-like \(n = 31\) | HER2 \(n = 17\) | \(P\) value |
|----------------|------------------------|-----------------------|----------------|-------------|
| Age (yrs)      | 46.0 ± 10.5            | 48.2 ± 10.8           | 47.5 ± 10.2    | 0.509       |
| Grade          | 25 (20.3%)             | 0 (0)                 | 0 (0)          | 0.000       |
| Tumor size (cm)| 25 (27.6%)             | 6 (19.4%)             | 5 (29.4%)      | 0.113       |
| Lymph node involvement | 63 (51.2%) | 16 (51.6%) | 9 (52.9%) | 0.991       |
| Stage          | 22 (22.0%)             | 6 (19.4%)             | 4 (23.5%)      | 0.981       |

\* \(P\) value obtained using the nonparametric Kruskal-Wallis test for continuous data and the exact chi-square test for categorical data.

---

**Figure 2 Examples of tissue microarrays with immunostaining for metalloproteinases (MMPs) and their tissue inhibitors of metalloproteinases (TIMPs).**
PR- and HER2+); basal-like (ER-α-, PR-, HER2- and EGFR or CK 5/6+); and unclassified (ER-α-, PR-, HER2-, EGFR-, and CK 5/6-) [8,9].

Several studies have shown that the basal-like and HER2-overexpressing subtypes have a higher histologic grade than the luminal subtype. In addition, the luminal subtype was shown to have better prognosis than the basal-like and HER2-overexpressing subtypes [21,22]. Likewise, the present study found that the basal-like and HER2-overexpressing subtypes showed a higher histologic grade than the luminal subtype. However, our study showed no statistically significant difference among the immunohistochemical-based molecular subtypes for overall and disease-free survival.

Therapy targeting the ER or HER2 oncogene is effective for the luminal and HER2-overexpressing subtypes. However, the basal-like subtype is resistant to targeted therapies such as hormonal therapy or trastuzumab therapy [10]. Hence, studies to identify specific targeted therapies for the basal-like subtype of breast carcinoma are needed.

### Table 2 Immunohistochemical results of MMPs and TIMPs in each subtype

| Characteristics | Tumor subtype |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|-----------------|---------------|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|                | Luminal A (n = 123) | Basal-like (n = 31) | HER2 (n = 17) |  |  |  |  |  |  |  |  |  |  |  |  |
|                 | Positive No/Cases (%) | Positive No/Cases (%) | Positive No/Cases (%) |  |  |  |  |  |  |  |  |  |  |  |  |  |
| MMP 1          | Tumoral 13/123 (10.6) | 3/31 (9.7) | 2/17 (11.8) | 1.000 |  |  |  |  |  |  |  |  |  |  |  |  |
|                 | Stromal 96/123 (78.0) | 22/31 (71.0) | 13/17 (76.5) | 0.470 |  |  |  |  |  |  |  |  |  |  |  |  |
| MMP 2          | Tumoral 47/123 (38.2) | 11/31 (35.5) | 7/17 (41.2) | 0.935 |  |  |  |  |  |  |  |  |  |  |  |  |
|                 | Stromal 4/123 (3.3) | 2/31 (6.5) | 0/17 (0) | 0.641 |  |  |  |  |  |  |  |  |  |  |  |  |
| MMP 7          | Tumoral 100/123 (81.3) | 31/31 (100) | 12/17 (70.6) | 0.005 |  |  |  |  |  |  |  |  |  |  |  |  |
|                 | Stromal 35/123 (28.5) | 11/31 (35.5) | 5/17 (29.4) | 0.767 |  |  |  |  |  |  |  |  |  |  |  |  |
| MMP 9          | Tumoral 28/123 (22.7) | 11/31 (35.5) | 12/17 (70.6) | 0.000 |  |  |  |  |  |  |  |  |  |  |  |  |
|                 | Stromal 6/123 (4.9) | 0/31 (0) | 0/17 (0) | 0.507 |  |  |  |  |  |  |  |  |  |  |  |  |
| MMP 11         | Tumoral 115/123 (93.5) | 30/31 (96.8) | 17/17 (100) | 1.000 |  |  |  |  |  |  |  |  |  |  |  |  |
|                 | Stromal 101/123 (82.1) | 29/31 (93.5) | 13/17 (76.5) | 0.253 |  |  |  |  |  |  |  |  |  |  |  |  |
| MMP 13         | Tumoral 45/123 (36.6) | 17/31 (54.8) | 12/17 (70.6) | 0.016 |  |  |  |  |  |  |  |  |  |  |  |  |
|                 | Stromal 9/123 (7.32) | 5/31 (16.1) | 5/17 (29.4) | 0.016 |  |  |  |  |  |  |  |  |  |  |  |  |
| MMP 14         | Tumoral 67/123 (54.5) | 21/31 (67.7) | 12/17 (70.6) | 0.331 |  |  |  |  |  |  |  |  |  |  |  |  |
|                 | Stromal 42/123 (34.1) | 5/31 (16.1) | 5/17 (29.4) | 0.118 |  |  |  |  |  |  |  |  |  |  |  |  |
| TIMP 1          | Tumoral 64/122 (52.5) | 12/31 (38.7) | 10/17 (58.8) | 0.274 |  |  |  |  |  |  |  |  |  |  |  |  |
|                 | Stromal 22/122 (18.0) | 4/31 (12.9) | 2/17 (11.8) | 0.748 |  |  |  |  |  |  |  |  |  |  |  |  |
| TIMP 2          | Tumoral 62/123 (50.4) | 16/31 (51.6) | 11/17 (64.7) | 0.657 |  |  |  |  |  |  |  |  |  |  |  |  |
|                 | Stromal 16/123 (13.0) | 6/31 (19.4) | 4/17 (23.5) | 0.368 |  |  |  |  |  |  |  |  |  |  |  |  |
| TIMP 3          | Tumoral 100/123 (81.3) | 27/31 (87.1) | 16/17 (94.1) | 0.605 |  |  |  |  |  |  |  |  |  |  |  |  |
|                 | Stromal 45/123 (36.6) | 18/31 (58.1) | 8/17 (47.1) | 0.107 |  |  |  |  |  |  |  |  |  |  |  |  |

*P* value obtained using the exact chi-square test.

Figure 3 Kaplan-Meier overall survival curves for stromal MMP-1 expression.

Figure 4 Kaplan-Meier disease-free survival curves according to tumoral TIMP-3 expression.
have been performed. Many individual markers such as stem cell marker Bmi-1, lysyl oxidase-like 2 (LOXL2), FOXC1, αβ1 integrin, and monocarboxylate transporter 1 were studied to find specific markers for basal-like breast carcinoma [23-27]. Lee et al. [28] found that the basal-like type of breast carcinoma displays a distinct promoter methylation pattern. Thus, we wanted to analyze the expression of MMPs and TIMPs in the three immunohistochemical-based subtypes of breast carcinoma to discover a potential therapeutic target of the basal-like subtype of breast carcinoma.

MMPs and TIMPs play a role in cancer progression including tumor growth, invasion and metastasis [13,14]. Numerous investigators have reported the significance of MMPs and TIMPs in breast carcinoma. Currently, 28 MMPs and 4 TIMPs are known to exist. Among these, MMP-1, 2, 9, 11, TIMP-1, 2 levels have been largely investigated in breast carcinoma tissues.

A few studies have previously investigated the expression of MMPs and TIMPs in various molecular subtypes of breast carcinoma. McGowan and Duffy [17] investigated the mRNA expression of MMPs in breast cancer by analysis of a published database. Using univariate analysis, they reported that, among 17 different MMPs, MMP-1, 9, 12, 14 and 15 were associated with poor outcome. Of the 5 MMPs, only MMP-14 was determined to be an independent predictor of patient outcome. They also investigated the differences of MMP expression between the basal subgroup and other subgroups (normal-type, luminal A, luminal B and HER-2). They found that mRNA expression of MMP-1, 7, 9, 12 and 15 was significantly elevated in the basal type compared with all the other subtypes combined. González et al. [19] performed an immunohistochemical study of MMP-1, 2, 7, 9, 11, 13, and 14 and TIMP-1, 2, and 3 on cancer specimens from 93 patients with luminal A (n = 48) or basal-like (n = 45) lesions. There were no significant differences in the expression of MMPs or TIMPs in the two phenotypes of tumors.

In the present study, we studied the expression MMPs and TIMPs in the luminal A and basal-like subtypes as well as in the HER2-overexpressing subtype, using a greater number of cases than the previous study by González et al. [19]. Because the crosstalk between cancer- and the surrounding stromal-cells is essential to fine tune the invasivity of cancer cells, we analyzed the differences in the immunoreactivity of MMPs (MMP-1, 2, 7, 9, 11, 13, and 14) and TIMPs (TIMP-1, 2, and 3) in the tumor tissue and in the surrounding stromal tissue of the three major immunohistochemical-based molecular subtypes of breast carcinoma.

Our results demonstrated some significant differences in the tumoral and stromal expression of MMPs and TIMPs depending on the immunohistochemical-based molecular subtype. The expression of tumoral MMP-9 was significantly elevated in the HER2-overexpressing subtype compared with the luminal A subtype and the basal-like subtype. The incidence of stromal MMP-13 expression was significantly higher in the HER2-overexpressing subtype than in the basal-like subtype. In agreement with our results, several studies have also shown that MMP-9 and MMP-13 are correlated with HER overexpression. MMP-9 (gelatinase B) is known to play a role in the invasion and metastasis of cancer through degradation of type IV collagen in the basement membrane and by inducing angiogenesis [29,30]. High MMP-9 expression was associated with HER2 overexpression [31-33]. MMP-13 (collagenase-3) expression in breast carcinomas was first reported by Freije et al. [34]. MMP-13 may play a key role in the MMP activation cascade [35]. Several studies suggested that MMP-13 might play a critical role in bone metabolism and even induce bone metastasis of breast cancer by activating MMP-9 and other enzymes [36-40]. Zhang et al. [41,42] reported that tumoral MMP-13 is correlated with HER2 expression.

Matrix metalloproteinase –7 degrades type IV collagen, fibronectin and laminin [16]. Dey et al. [43] found that MMP-7 mRNA level was high in the triple negative breast cancer and this result was associated to the loss of PTEN. Our study showed that tumoral MMP-7 expression was significantly higher in the basal-like subtype compared the luminal A subtype as well as the

| Table 3 Multivariate analysis with Cox’s proportional hazards model for prognostic factors in breast cancer patients |
|---------------------------------|------------------|-----------------|-----------------|-------------------|
| Tumor size (≤2 or >2 cm)        | Overall survival |
|                                 | Disease-free survival |
| HR    | 95% CI | P-value*   | HR    | 95% CI | P-value*   |
|-------|--------|------------|-------|--------|------------|
| Lymph node status (negative or positive) | 2.873 | 0.85-9.73 | 0.090 | 3.153 | 0.93-10.71 | 0.067 |
| Stage (I, II or III)             | 1.088 | 0.45-2.62 | 0.851 | 1.988 | 0.83-4.75  | 0.122 |
| Stromal MMP-1 expression (negative or positive) | 4.454 | 2.46-8.06 | 0.000 | 3.577 | 1.926-6.643 | 0.000 |
| Tumor TIMP-3 expression (negative or positive) | 0.528 | 0.29-0.98 | 0.042 | -     | -          | -      |

* Multivariate analysis was carried out on all variables that were found to be significant in univariate analysis. HR, hazard rate; CI, confidence interval; --, not significant in univariate analysis.
HER2-overexpressing subtype. We also found that the incidence of tumoral MMP-13 expression was significantly higher in the basal-like subtype than in the HER2-overexpressing subtype. TIMP-3 may be an important component in inhibiting angiogenesis and stimulating apoptosis [13]. Mylona et al. [44] reported that reduced expression of tumoral TIMP-3 protein was correlated with an aggressive tumor phenotype and shortened disease-free survival in lymph-node-positive patients. Likewise, Span et al. [45] found that high tumor levels of TIMP-3 was associated with longer relapse-free survival in breast cancer patients treated with tamoxifen. Conversely, Vizoso et al. [16] reported that TIMP-3 expression by stromal cells correlated positively with the occurrence of distant metastases. Similarly, del Casar et al. [46] demonstrated that stromal TIMP-3 expression was elevated in primary tumors of patients with distant metastasis, although the result was not statistically significant. Jiang et al. [47] also found that TIMP-3 expression was higher in breast cancer with lymph node metastasis than in those without metastasis. However, the explanation for this discrepancy remains unknown. One possible explanation for these differences can be attributed to the different methods used for the assessment of TIMP3 expression. The present study demonstrated that, in a univariate analysis, TIMP-3 expression was significantly associated with shortened disease-free survival in patients with breast carcinoma. However, in a multivariate analysis, tumoral TIMP-3 expression was not determined as an independent prognostic factor for poor disease-free survival (\( P = 0.133 \)).

Vizoso et al. [16] found that high expression of MMP-1 by fibroblasts was associated to the metastases. Przybylowska [48] et al. described that MMP-1 correlated with the local invasion. Conversely, in the present study, stromal MMP-1 expression was determined as an independent prognostic factor for good overall survival.

In the present study, tumoral MMP-7 and tumoral MMP-13 expression was higher in the basal-like subtype than the luminal A subtype or the HER2-overexpressing subtype. However, we could not find the prognostic significance of MMP-7 and MMP-13 in the basal-like subtype. A caveat with our study is that the specificities of commercial antibodies used were not proven using in situ hybridization, which may contribute to differences between studies. Our study is also limited by the small number of cases of the basal-like subtype. Therefore, more studies using a much larger sample size, especially those with the basal-like breast carcinoma, are needed to define the potential prognostic role of MMPs and TIMPs in breast carcinoma. Also, additional studies are needed to determine the mechanisms underlying the differences of MMPs expression in the molecular phenotypes of breast cancer.

Conclusion

Our research demonstrated some significant differences between MMP and TIMP expression in three immunohistochemical-based molecular subtypes. Tumoral MMP-7 and tumoral MMP-13 expression were significantly higher in the basal-like subtype compared to the luminal A subtype or the HER2-overexpressing subtype. Further studies are required to identify the distinct role of MMPs and TIMPs in the basal-like breast carcinoma.

Abbreviations

MMP: metalloproteinase; TIMP: tissue inhibitors of metalloproteinase (TIMP); ER-α: estrogen receptor-α; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2; CK: cytokeratin; EGFR: epidermal growth factor receptor.

Competing interests

The authors declare no financial or other conflicts of interest.

Author’s contributions

GEK worked on literature research, study design, experimental work, data interpretation, and drafting the manuscript. MHP and JHY carried out the data collection. JSL was involved in the study design, data collection and experiments in the study. JHL and JHN helped with data collection and experiments in the study. JSL was involved in the study design, data collection and experiments in the study. YDC and KHL helped with data collection and experiments in the study. JSL was involved in the study design, data collection and experiments in the study. JSL was involved in the study design, data collection and experiments in the study. KHL helped with data collection and experiments in the study. JSH carried out the hybridization, which may contribute to differences between studies. Our study is also limited by the small number of cases of the basal-like subtype. Therefore, more studies using a much larger sample size, especially those with the basal-like breast carcinoma, are needed to define the potential prognostic role of MMPs and TIMPs in breast carcinoma. Also, additional studies are needed to determine the mechanisms underlying the differences of MMPs expression in the molecular phenotypes of breast cancer.

References

1. Ku SS. Korean Breast Cancer Society: Chronological changing patterns of clinical characteristics of Korean breast cancer patients during 10 years (1996–2006) using nationwide breast cancer registration on-line program: biannual update. J Surg Oncol 2008, 98:318–323.

2. Reis-Filho JS, Lakhani SR. Breast cancer special types: why bother? J Pathol 2008, 216:394–398.

3. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR. Molecular evolution of breast cancer. J Pathol 2005, 205:249–254.

4. Sarlie T, Perrou CM, Tlibshirani R, Aaz T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffery SS, Thorsen T, Quist H, Matouse JC, Brown PO, Botstein D, Lanning PE, Barresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2003, 100:8418–8423.

5. Sotiriou C, Neo SY, McShane LM, El K, Long PM, Jazayeri A, Mantla P, Fox SB, Harris AL, Liu ET. Breast cancer classification and prognosis based on
gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003, 100:10393–10398.
7. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkvloot RM, Roberts C, Linley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:841–847.
8. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Li H, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Askins LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5376–5374.
9. Marotti JD, Collins LC, Hu R, Tamimi AR: Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study. Mod Pathol 2010, 23:91–204.
10. Rakha EA, Reis-Filho JS, Ellis IO: Basal-like breast cancer: a critical review. J Clin Oncol 2008, 26:2568–2581.
11. Vu TH, Verbeek J: Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 2000, 14:2123–2133.
12. Fassina G, Ferrari N, Brigati C, Bennelli R, Santi L, Noonan DM, Albini A: Tissue inhibitors of metalloproteinases: regulation and biological activities. Clin Exp Metastasis 2000, 18:111–120.
13. Jiang Y, Goldberg ID, Shi YC: Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002, 21:2245–2252.
14. Deryugina EI, Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006, 25:9–34.
15. Singleton B: Matrix metalloproteinases as valid clinical targets. Curr Pharm Des 2007, 13:333–346.
16. Vizio FJ, González LO, Cortéz MD, Rodríguez JC, Vázquez J, Lamelas ML, Junquera S, Merino AM, García-Muñiz JL: Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer 2007, 96:903–911.
17. McGowan PM, Duffy MJ: Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. Ann Oncol 2008, 19:1566–1572.
18. Figueira RC, Gomes LR, Neto JS, Silva FC, Silva ID, Sogayar MC: Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer 2009, 9:20.
19. González LO, Cortéz MD, Junquera S, González-Fernández R, del Casar JM, García C, Andochoa A, Vázquez J, Pérez-Fernández R, Vizio FJ: Expression and prognostic significance of metalloproteinases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma. Hum Pathol 2009, 40:1224–1233.
20. Bae YK, Gong GY, Kang J, Lee AW, Cho EY, Lee JS, Suh KS, Lee DW, Jung WH: The Breast Pathology Study Group of Korean Society of Pathologists: HER2 Status by High Standardized Immunohistochemistry and Silver-Enhanced In Situ Hybridization in Korean Breast Cancer. J Breast Cancer 2012, 15:381–387.
21. Carey LA, Perou CM, Livasy CA, Duggan D, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmonston S, Derng SL, Gerads M, Cheang MC, Nielsen TO, Moorman PG, Eap HS, Miklan RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2902–2902.
22. Tang P, Skinner KA, Hicks DG: Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready? Diagn Mol Pathol 2009, 18:125–132.
23. Wang Y, Zhe H, Ding Z, Gao P, Zhang N, Li G: Cancer stem cell marker Bmi-1 expression is associated with basal-like phenotype and poor survival in breast cancer. World J Surg 2012, 36:1189–1194.
24. Moreno-Bueno G, Salvador F, Martín A, Floristán A, Cuevas EP, Santos V, Nieminen LM, van 't Veer LJ, Martín A, Floristán A, Cuevas EP, Santos V, Nieminen LM, van 't Veer LJ, Martín A, Floristán A, Cuevas EP, Santos V, Nieminen LM: Basal-like breast cancer displays distinct patterns of promoter methylation. Cancer Biol Ther 2010, 9:1017–1024.
25. Jones LS, Walker RA: Control of matrix metalloproteinase activity in cancer. J Pathol 1997, 183:377–379.
26. Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2:161–174.
27. Sulli Y, Deming GG, Yildirim A, Karagöz F, Kandemir B: Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast. Pathol Res Pract 2011, 207:747–753.
28. Pellikainen JM, Rooponen KM, Kataja WV, Kellkossi JK, Eskelinen MJ, Kosma VM: Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 2004, 10:7621–7628.
29. Faturumlu M, Shelton J, Azonica SM: MMP-9 increases HER2/neu expression and alters apoptosis levels in human mammary epithelial cells (HMEC). Breast Cancer Res Treat 2012, 135:519–530.
30. Freije JM, Diez-Izeta I, Balbin M, Sánchez LM, Blasco R, Tolvía J, López-Otin C: Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 2004, 279:16766–16773.
31. Leeman MF, Curran S, Murray GI: The structure, regulation, and function of human matrix metalloproteinase-13. Crit Rev Biochem Mol Biol 2002, 37:149–166.
32. Knauer V, Smith B, López-Otin C, Murphy G: Activation of progelatinase B (proMMP-9) by active collagenase-3 (MMP-3). Eur J Biochem 1997, 248:369–375.
33. Ivett E, Scapolan M, Pecolo M, Wassermann B, Abu-Rumieh I, Balestrieri L, Bosatti E, Tripodo C, Colombatti A, Sposetto P: MMP-13 stimulates osteoclast differentiation and activation in tumour breast bone metastases. Breast Cancer Res 2011, 13:R105.
34. Ibaragi S, Shimot H, Hassan NW, Isowa S, Kurio N, Mandai H, Kodama S, Sasaki S: Induction of MMP-13 expression in bone-metastasizing cancer cells by type I collagen through integrin αvβ3 and αvβ5: a potential prognostic biomarker with functional significance in basal-like breast cancer: a novel cell-surface marker of the basal phenotype that promotes tumour cell invasion. J Pathol 2011, 223:646–658.
35. Pinheiro C, Albergaria A, Paredes J, Sousa B, Dufoño R, Viera D, Schmitt F, Baltazar F: Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma. Histopathology 2010, 56:860–867.
36. Lee JS, Flacker MJ, Lee JT, Choi C, Park MH, Yoon JT, Zhang Z, Sukumar S: Basal-like breast cancer displays distinct patterns of promoter methylation. Cancer Biol Ther 2010, 9:1017–1024.
37. Jones LS, Walker RA: Control of matrix metalloproteinase activity in cancer. J Pathol 1997, 183:377–379.
38. Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2:161–174.
39. Sulli Y, Deming GG, Yildirim A, Karagöz F, Kandemir B: Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast. Pathol Res Pract 2011, 207:747–753.
40. Pellikainen JM, Rooponen KM, Kataja WV, Kellkossi JK, Eskelinen MJ, Kosma VM: Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 2004, 10:7621–7628.
metalloproteases and their inhibitors in primary tumors and in local recurrences after mastectomy for breast cancer. J Cancer Res Clin Oncol 2010; 136:1049–1058.

47. Jiang X, Huang X, Li J, Shi Y, Zhou L. Relationship between tissue inhibitors of metalloproteinase and metastasis and prognosis in breast cancer. Zhonghua Wai Ke Za Zhi 2000; 38:291–295. 19.

48. Przybyłowska K, Kluczna A, Zadrozny M, Krawczyk T, Kulig A, Rykala J, Kołacinska A, Morawiec Z, Drzewoski J, Blasiak J. Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat 2006; 95:65–72.

do:10.1186/1471-2407-14-959
Cite this article as: Kim et al.: Expression of matrix metalloproteinases and their inhibitors in different immunohistochemical-based molecular subtypes of breast cancer. BMC Cancer 2014 14:959.